Abstract:OBJECTIVES/SPECIFIC AIMS: MicroRNAs (miRNA) affect transcription of a number of genes involved in the development and progression of diabetic nephropathy (DN), and have become attractive therapeutic targets and biomarkers. Elevated renal gluconeogenesis, fibrosis, and albuminuria are early markers of incipient DN. Recent studies report that renal miRNA-451 may protect against DN and reduce renal gluconeogenesis in rodent models. MiRNA-451 is thought to act by targeting select factors resulting from disrupted insulin and growth factor signaling and the mechanistic-target of rapamycin (mTOR) in early DN. This study aimed to elucidate the role of miRNA-451 in the development and progression of DN. METHODS/STUDY POPULATION: To further elucidate the role of miRNA-451 in DN, we placed male insulin-resistant, TALLYHO/Jng mice on a high-fat diet (60% kCal). The mice were divided into 2 treatment groups and received 8 consecutive weekly intraperitoneal injections of locked nucleic acid (LNA) miR-451-inhibitor or LNA-scrambled compound (2 mg/kg·bw; n=8/treatment). Mice were euthanized after 12 weeks (4 weeks sans injections) and kidneys, liver, pancreas and abdominal adipose tissue were harvested for analysis. RESULTS/ANTICIPATED RESULTS: Renal homogenate expression of miRNA-451 was drastically reduced in inhibitor-treated mice (~6-fold) in comparison with scramble-treated mice. Western blotting of cortex homogenates for indicators of fibrosis and targets of miRNA-451 revealed a significant reduction in collagen IV (marker of epithelial integrity) in inhibitor-treated mice. In addition, metalloproteinase type 9 (MMP9, a known type IV collagenase), YWHAZ (a scaffolding protein and known target of miR-451), mTOR, and fructose bisphosphatase (FBP1, a rate-limiting gene in gluconeogenesis) were significantly increased in this group in comparison to scramble-treated mice. However, no differences were found in protein levels for glucose-6-phosphatase (G-6-Pase) or phosphoenolpyruvate (PEPCK), 2 additional gluconeogenic rate-limiting genes. MiRNA-451 antagonist did not significantly affect final body weight or blood glucose; however, mean blood sodium concentrations were slightly, but significantly higher (2%) in the LNA-inhibitor treated group (when compared with the scramble-treated group). No differences in blood potassium or chloride were found. Anion gap was 90% higher in the LNA-inhibitor treated group when compared with scramble-treated mice. No differences in urinary albumin to creatinine ratio were found between the two treatment groups. However, Masson Trichrome scoring revealed a 59% increase in fibrosis in inhibitor-treated mice. DISCUSSION/SIGNIFICANCE OF IMPACT: Collectively, these findings support a potentially protective role of miRNA-451 in attenuating signaling via mTOR that may alter both renal gluconeogenic potential (contributing to the diabetic phenotype) and activation and progression of renal fibrosis. Therapies to enhance miRNA-451 signaling may be beneficial to reduce renal pathology associated with DN.

Mir-92b-3p Is Induced By Advanced Glycation End Products And Involved In The Pathogenesis Of Diabetic Nephropathy

MiR-185-3p Downregulates Advanced Glycosylation End Product Receptor Expression and Improves Renal Function in Diabetic Nephropathy Mice.

Abstract 050: mir-192-5p in the Kidney is Protective Against the Development of Hypertension

MicroRNA-29b Inhibits Diabetic Nephropathy in Db/db Mice.

Involvement of Inflammation-Related Mir-155 and Mir-146A in Diabetic Nephropathy: Implications for Glomerular Endothelial Injury

Role of Microrna-214-targeting PTEN in Advanced Glycation Endproducts-Induced Apoptosis Delay of Monocytes (89.35)

Abated microRNA-195 expression protected mesangial cells from apoptosis in early diabetic renal injury in mice

Role of microRNA-214-targeting phosphatase and tensin homolog in advanced glycation end product-induced apoptosis delay in monocytes.

Effects of Advanced Glycation End Products on Activity and Expression of Matrix Metalloproteinase-2 in Renal Cortex of Rats

Differential Expression and Therapeutic Efficacy of Microrna-346 in Diabetic Nephropathy Mice

miR-30a-5p targets Becn1 to ameliorate high-glucose-induced glomerular podocyte injury in immortalized rat podocyte cell line

Effect of Mir-21 on Renal Fibrosis by Regulating MMP-9 and TIMP1 in Kk-Ay Diabetic Nephropathy Mice

MiRNA-133a-3p Attenuates Renal Tubular Epithelial Cell Injury via Targeting MALM1 and Suppressing the Notch Signaling Pathway in Diabetic Nephropathy

2466 MicroRNA-451: A potential key player in the development of diabetic nephropathy in an insulin resistant mouse model

miR-21-3p regulates AGE/RAGE signalling and improves diabetic atherosclerosis

Role of microRNA-215 in nephropathy of type 2 diabetic db/db mice

Advanced Glycation End Products Increased Angiopoietin-1 Expression Via Oxidative Stress and NF-κB Pathways in Cultured NRK-49F Cells

Mir-98-5p Alleviated Epithelial-to-Mesenchymal Transition and Renal Fibrosis Via Targeting Hmga2 in Diabetic Nephropathy

Inhibition of NA(+)/H(+) Exchanger 1 Attenuates Renal Dysfunction Induced by Advanced Glycation End Products in Rats.

Inhibition of p53/miR-34a/SIRT1 axis ameliorates podocyte injury in diabetic nephropathy

MiRNAs Expression Profiles in the Early Stage of Diabetic Mice